ReviewImmune network2026
Integrative Roles of NK Receptors and γδ TCRs in γδ T Cell-Mediated Cancer Immunity.
Review in Immune network, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- NKR-P1A/CD161: A Multifunctional Immune Receptor at the Crossroads of Antitumor Immunity.Biomolecules · 2026Review
- The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis.British journal of haematology · 2026Article
- Dynamic Interplay Between Tumor Cells and the Immune System.Immune network · 2026Article
- Divergent cytotoxic and inflammatory functions of intratumoral Vδ2Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
γδ T cells employ dual recognition strategies that integrate innate and adaptive immune sensing through NK receptors (NKRs) and γδ-TCRs in cancer immunity. Through the coordinated use of clonotypic γδ-TCRs and germline-encoded NKRs, γδ T cells recognize malignant cells in an MHC-unrestricted manner and exert potent cytotoxic and immunomodulatory functions. In this review, we discuss how activating and inhibitory NKRs-including NKG-2D, natural cytotoxicity receptors, CD16, NKG-2A, and killer cell immunoglobulin-like receptors-are expressed across major human γδ T cell subsets and how their signals are integrated with γδ-TCRs. We highlight subset-specific differential utilization of NKRs in circulating Vδ2 and tissue-resident Vδ1 γδ T cells, context-dependent integration of γδ-TCR and NKR signaling within the tumor microenvironment, and emerging implications for γδ T cell-based cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.